In Vitro DiagnosticsPreTect HPV-Proofer 7^®

• Not all HPV genotypes carry the same risk. The goal is to find the ones that trigger Cervical Cancer and pre-empt it.
• The E6/E7 mRNA test with the strongest predictive value. ¹
• High specificity triage in ASC-US and grade 1 cervical intraepithelial neoplasia (CIN 1) cytology diagnosis.
• Identification of precursor lesions most likely to progress to invasive cancer.
• Higher specificity than other tests, resulting in accurate patient management and avoiding unnecessary treatment.
• Only for use by healthcare professionals.
• Intrinsic sample control to check specimen quality and detect factors inhibiting amplification.

_{¹ “HPV E6/E7 mRNA test for the detection of high-grade cervical intraepithelial neoplasia”}

• The main cause of Cervical Cancer is the presence of E6/E7 oncoproteins in HPV.
• More than 90% of cervical cancer cases worldwide are caused by HPV genotypes 16, 18, 31, 33, 45, 52, and 58. ¹
• Cervical Cancer is the only cancer that is 100% preventable, if HR-HPV is detected early.
• The optimal detection strategy requires high specificity and accurate individual patient management to minimize unnecessary treatment due to false positives.

_{¹ WHO. https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer}

PreTect HPV-Proofer 7® is based on NASBA technology, an enzymatic amplification process that can amplify and detect RNA even in the presence of DNA. Unlike PCR, an amplification run is performed under isothermal conditions at 41°C, achieving a fast result.